JP2010500962A - システインプロテアーゼ類のエポキシド阻害剤 - Google Patents

システインプロテアーゼ類のエポキシド阻害剤 Download PDF

Info

Publication number
JP2010500962A
JP2010500962A JP2009515635A JP2009515635A JP2010500962A JP 2010500962 A JP2010500962 A JP 2010500962A JP 2009515635 A JP2009515635 A JP 2009515635A JP 2009515635 A JP2009515635 A JP 2009515635A JP 2010500962 A JP2010500962 A JP 2010500962A
Authority
JP
Japan
Prior art keywords
group
alkyl
infection
compound according
disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2009515635A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010500962A5 (enExample
Inventor
マシュー エス． ボギョ，
アミール エム． サダギアニ，
スティーブン ベルヘルスト，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Leland Stanford Junior University
Original Assignee
Leland Stanford Junior University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Leland Stanford Junior University filed Critical Leland Stanford Junior University
Publication of JP2010500962A publication Critical patent/JP2010500962A/ja
Publication of JP2010500962A5 publication Critical patent/JP2010500962A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D303/00—Compounds containing three-membered rings having one oxygen atom as the only ring hetero atom
    • C07D303/02—Compounds containing oxirane rings
    • C07D303/04—Compounds containing oxirane rings containing only hydrogen and carbon atoms in addition to the ring oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/04—Amoebicides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/10—Anthelmintics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D303/00—Compounds containing three-membered rings having one oxygen atom as the only ring hetero atom
    • C07D303/02—Compounds containing oxirane rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D303/00—Compounds containing three-membered rings having one oxygen atom as the only ring hetero atom
    • C07D303/02—Compounds containing oxirane rings
    • C07D303/48—Compounds containing oxirane rings with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms, e.g. ester or nitrile radicals

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Neurology (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Dermatology (AREA)
  • Obesity (AREA)
  • Psychiatry (AREA)
  • Molecular Biology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Transplantation (AREA)
  • Emergency Medicine (AREA)
JP2009515635A 2006-06-13 2007-06-13 システインプロテアーゼ類のエポキシド阻害剤 Pending JP2010500962A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US81363906P 2006-06-13 2006-06-13
PCT/US2007/071145 WO2008042480A2 (en) 2006-06-13 2007-06-13 Epoxide inhibitors of cysteine proteases

Publications (2)

Publication Number Publication Date
JP2010500962A true JP2010500962A (ja) 2010-01-14
JP2010500962A5 JP2010500962A5 (enExample) 2010-07-29

Family

ID=39269056

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009515635A Pending JP2010500962A (ja) 2006-06-13 2007-06-13 システインプロテアーゼ類のエポキシド阻害剤

Country Status (11)

Country Link
US (1) US8673904B2 (enExample)
EP (1) EP2029135A4 (enExample)
JP (1) JP2010500962A (enExample)
KR (1) KR20090029725A (enExample)
CN (1) CN101808634A (enExample)
AU (1) AU2007305138A1 (enExample)
BR (1) BRPI0712868A2 (enExample)
CA (1) CA2655139A1 (enExample)
IL (1) IL195782A0 (enExample)
RU (1) RU2009100878A (enExample)
WO (1) WO2008042480A2 (enExample)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015510508A (ja) * 2012-02-01 2015-04-09 ザ トラスティーズ オブ コロンビア ユニヴァーシティ イン ザ シティ オブ ニューヨーク 新規のシステインプロテアーゼ阻害剤及びその使用
JP2016520101A (ja) * 2013-05-31 2016-07-11 インスティテュート オブ ファーマコロジー アンド トキシコロジー アカデミー オブ ミリタリー メディカル サイエンシズ ピー．エル．エー．チャイナ ２，３−ブタンジアミドエポキシド化合物ならびにその調製方法及び使用
WO2024181576A1 (ja) * 2023-03-02 2024-09-06 日本メジフィジックス株式会社 放射性金属標識抗体、放射性医薬、及び化合物

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3296295A1 (en) 2009-08-07 2018-03-21 American Life Science Pharmaceuticals, Inc. Compositions and methods for treating beta-amyloid related diseases
WO2011075678A1 (en) 2009-12-18 2011-06-23 The Board Of Trustees Of The Leland Stanford Junior University Specific inhibitors and active site probes for legumain
WO2012142003A2 (en) 2011-04-15 2012-10-18 Life Technologies Corporation Chemical ligation
CN107151236B (zh) * 2016-03-03 2021-04-30 中国人民解放军军事医学科学院毒物药物研究所 一种2,3-环氧丁二酰衍生物及其制备方法和用途
EP3681494A4 (en) * 2017-09-15 2021-08-04 Ampersand Biopharmaceuticals, Inc. INHIBITION OF SPONTANEOUS METASTASIS BY PROTEIN INHIBITORS OF CYSTEIN PROTEASES
JP2020534285A (ja) 2017-09-15 2020-11-26 アンパサンド バイオファーマシューティカルズ インコーポレイテッドＡｍｐｅｒｓａｎｄ Ｂｉｏｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃ． 投与および処置の方法
CN110241438A (zh) * 2018-03-08 2019-09-17 天津大学 泡沫铜担载钯铜合金纳米笼催化剂及其制备方法
US11905249B2 (en) 2021-01-25 2024-02-20 Jackson State University Covalent inhibitors of equine encephalitis virus
KR20230165715A (ko) 2022-05-27 2023-12-05 서울대학교산학협력단 기생충 감염증의 예방 또는 치료용 약학 조성물

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS55115878A (en) * 1979-02-27 1980-09-06 Taisho Pharmaceut Co Ltd Epoxysuccinic acid derivative
JPH04139182A (ja) * 1990-09-29 1992-05-13 Taisho Pharmaceut Co Ltd エポキシスクシナム酸誘導体およびその中間体
JPH08104683A (ja) * 1993-10-29 1996-04-23 Takeda Chem Ind Ltd エポキシコハク酸誘導体
JPH08104684A (ja) * 1994-05-31 1996-04-23 Takeda Chem Ind Ltd エポキシコハク酸関連化合物
WO1997021694A1 (en) * 1995-12-12 1997-06-19 Taiho Pharmaceutical Co., Ltd. Epoxysuccinamide derivatives or salts thereof, and drugs containing the same
WO1998047887A1 (en) * 1997-04-18 1998-10-29 Taiho Pharmaceutical Co., Ltd. Novel epoxysuccinamide derivatives or salts thereof
JPH11263783A (ja) * 1998-01-09 1999-09-28 Taisho Pharmaceut Co Ltd エポキシスクシナム酸誘導体

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1469797A (en) 1974-11-07 1977-04-06 Pfizer Ltd Antibacterial cephalosporin derivatives
US4172896A (en) 1978-06-05 1979-10-30 Dainippon Pharmaceutical Co., Ltd. Methane-sulfonamide derivatives, the preparation thereof and composition comprising the same
JPS55153778A (en) 1979-05-17 1980-11-29 Taisho Pharmaceut Co Ltd Epoxysuccinylamino acid derivative
JPS57169478A (en) 1981-04-10 1982-10-19 Nippon Chemiphar Co Ltd Piperazine derivative
JPS6276A (ja) 1985-03-26 1987-01-06 Toyo Jozo Co Ltd 酵素阻害性新規物質
GB9217295D0 (en) 1992-08-14 1992-09-30 Wellcome Found Controlled released tablets
US5358970A (en) 1993-08-12 1994-10-25 Burroughs Wellcome Co. Pharmaceutical composition containing bupropion hydrochloride and a stabilizer
US5541231A (en) 1993-07-30 1996-07-30 Glaxo Wellcome Inc. Stabilized Pharmaceutical
GB9315856D0 (en) 1993-07-30 1993-09-15 Wellcome Found Stabilized pharmaceutical
US5556853A (en) 1993-10-29 1996-09-17 Takeda Chemical Industries, Ltd. Epoxysuccinic acid derivatives
AU2537695A (en) 1994-05-31 1995-12-21 Takeda Chemical Industries Ltd. Epoxysuccinic acid derivatives, their production and use
AU2483599A (en) 1998-01-29 1999-08-16 Sepracor, Inc. Pharmaceutical uses of optically pure (-)-bupropion
WO2002038540A2 (en) 2000-11-10 2002-05-16 The Regents Of The Univeristy Of California Activity-dependent cysteine protease profiling reagent
EP1425330B1 (en) 2001-09-12 2005-03-09 Dow Global Technologies Inc. Network polymers comprising epoxy-terminated esters
US20030212003A1 (en) 2002-02-14 2003-11-13 Hermann Lubbert Cathepsin Y for the development of a medicament for the treatment of pain
WO2006074466A2 (en) 2005-01-10 2006-07-13 The Board Of Trustees Of The Lelands Stanford Junior University Synthesis of epoxide based inhibitors of cysteine proteases

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS55115878A (en) * 1979-02-27 1980-09-06 Taisho Pharmaceut Co Ltd Epoxysuccinic acid derivative
JPH04139182A (ja) * 1990-09-29 1992-05-13 Taisho Pharmaceut Co Ltd エポキシスクシナム酸誘導体およびその中間体
JPH08104683A (ja) * 1993-10-29 1996-04-23 Takeda Chem Ind Ltd エポキシコハク酸誘導体
JPH08104684A (ja) * 1994-05-31 1996-04-23 Takeda Chem Ind Ltd エポキシコハク酸関連化合物
WO1997021694A1 (en) * 1995-12-12 1997-06-19 Taiho Pharmaceutical Co., Ltd. Epoxysuccinamide derivatives or salts thereof, and drugs containing the same
WO1998047887A1 (en) * 1997-04-18 1998-10-29 Taiho Pharmaceutical Co., Ltd. Novel epoxysuccinamide derivatives or salts thereof
JPH11263783A (ja) * 1998-01-09 1999-09-28 Taisho Pharmaceut Co Ltd エポキシスクシナム酸誘導体

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
JPN6013000705; Ｔｅｔｒａｈｅｄｒｏｎ Ｖｏｌ．５６, 2000, Ｐ．９７４７-９７６２ *
JPN6013048824; Ｓｙｎｔｈｅｓｉｓ Ｎｏ．ＳＩ, 1999, Ｐ．１５００-１５０４ *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015510508A (ja) * 2012-02-01 2015-04-09 ザ トラスティーズ オブ コロンビア ユニヴァーシティ イン ザ シティ オブ ニューヨーク 新規のシステインプロテアーゼ阻害剤及びその使用
US10647709B2 (en) 2012-02-01 2020-05-12 The Trustees Of Columbia University In The City Of New York Cysteine protease inhibitors and uses thereof
JP2016520101A (ja) * 2013-05-31 2016-07-11 インスティテュート オブ ファーマコロジー アンド トキシコロジー アカデミー オブ ミリタリー メディカル サイエンシズ ピー．エル．エー．チャイナ ２，３−ブタンジアミドエポキシド化合物ならびにその調製方法及び使用
WO2024181576A1 (ja) * 2023-03-02 2024-09-06 日本メジフィジックス株式会社 放射性金属標識抗体、放射性医薬、及び化合物

Also Published As

Publication number Publication date
US20080176841A1 (en) 2008-07-24
EP2029135A4 (en) 2011-08-17
AU2007305138A1 (en) 2008-04-10
WO2008042480A3 (en) 2008-08-14
RU2009100878A (ru) 2010-07-20
CA2655139A1 (en) 2008-04-10
US8673904B2 (en) 2014-03-18
IL195782A0 (en) 2009-09-01
KR20090029725A (ko) 2009-03-23
WO2008042480A2 (en) 2008-04-10
EP2029135A2 (en) 2009-03-04
BRPI0712868A2 (pt) 2013-05-07
CN101808634A (zh) 2010-08-18

Similar Documents

Publication Publication Date Title
JP2010500962A (ja) システインプロテアーゼ類のエポキシド阻害剤
JP7659015B2 (ja) 免疫調節剤としての１，２，４－オキサジアゾールおよびチアジアゾール化合物
RU2450016C2 (ru) Пептидные эпоксикетоны для ингибирования протеасомы
KR100659651B1 (ko) 시클릭 아미드 유도체
SK13072002A3 (sk) Deriváty cyklických beta-aminokyselín ako inhibítory matrixových metaloproteáz a TNF-alfa
UA46821C2 (uk) Заміщені n-[(аміноімінометил або амінометил)феніл]пропіламіди, фармацевтична композиція, способи лікування та проміжні сполуки
JP2001525809A (ja) プロテアーゼ阻害剤
WO1998008802A1 (en) Inhibitors of cysteine protease
NZ520588A (en) Protease inhibitors
JPH06192199A (ja) ケトン誘導体
JP2003513956A (ja) プロテアーゼ阻害剤
EP1079821A1 (en) Protease inhibitors
EP1140897A1 (en) Protease inhibitors
JP2003513922A (ja) プロテアーゼ阻害剤
JP2003513926A (ja) プロテアーゼ阻害剤
JP2003513924A (ja) プロテア−ゼ阻害剤
WO2020166592A1 (ja) ヘミアスタリン誘導体とその抗体薬物複合体
JP2003513921A (ja) プロテア−ゼ阻害剤
US20040157828A1 (en) Protease inhibitors
JP2003513972A (ja) プロテアーゼ阻害剤
CN101326172A (zh) 茉莉酮酸酯衍生物、药物组合物及它们的使用方法
HUP0301964A2 (en) Protease inhibitors
JP2003513927A (ja) プロテア−ゼ阻害剤
JP7323238B2 (ja) アミノキシ酸系抗がん幹細胞化合物およびその方法
US11149062B2 (en) HDAC inhibitors and methods of treatment using the same

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100608

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20100608

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20130115

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20130412

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20130419

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20130515

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20130522

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130614

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20131001

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20131226

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20140109

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20140120

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20140127

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140401

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20140812